|
Title
|
|
|
|
The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy
|
|
|
Author
|
|
|
|
|
|
|
Institution/Organisation
|
|
|
|
A0081007 Investigators
|
|
|
Abstract
|
|
|
|
| We evaluated the efficacy of pregabalin in patients with chronic lumbosacral radiculopathy. This randomized, controlled, withdrawal trial included five phases: screening (418 days); run-in (410 days) to screen out placebo responders; single-blind (28 days) to identify pregabalin responders; double-blind to randomize responders to pregabalin or placebo (35 days); and final study medication taper (7 days). The primary endpoint was time to loss of response (LOR) during the double-blind phase (⩾1-point increase in pain, discontinuation, or rescue-medication use). In the single-blind phase, 58% of patients had ⩾30% pain reduction. In the double-blind phase, pregabalin (n = 110) and placebo (n = 107) groups did not differ significantly in time to LOR. Adverse events caused the discontinuation of 9.9% and 5.6% of pregabalin-treated and placebo-treated patients, respectively. Most patients with chronic lumbosacral radiculopathy responded to pregabalin therapy; however, time to LOR did not significantly differ between pregabalin and placebo. Considering the results of all phases of the study, it is difficult to draw definitive conclusions from it, suggesting a need for further work to understand the clinical potential of pregabalin treatment for lumbosacral radiculopathy. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Pain / International Association for the Study of Pain. - Amsterdam
Pain / International Association for the Study of Pain. - Amsterdam
|
|
|
Publication
|
|
|
|
Amsterdam
:
2010
|
|
|
ISSN
|
|
|
|
0304-3959
|
|
|
Volume/pages
|
|
|
|
150
:3
(2010)
, p. 420-427
|
|
|
ISI
|
|
|
|
000281675000012
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|